Steen Andersen
CEO at PROBIOTIX HEALTH PLC
Replay available
Audited results for the year ended 31 December 2025 hosted by ProBiotix Health (AQUIS:PBX) on Investor Meet Company, held 2026-03-30.

On 6ix: 6ix.com/event/probiotix-health-plc-pbx-audited-results-for-the-year-ended-31-december-2025
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:01 Good morning, and welcome to the PROBIOTIX HEALTH PLC Annual Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged, and they can be submitted at any time using the q and a tab situated on the right hand corner of your screen. Just simply type in your questions and press send. Before we begin, I would like to submit the following poll, and I would now like to hand you over to CEO, Steen Anderson. Good morning to you, sir. Good morning. Thank you, and good morning to everyone joining. Thank you for joining this morning's presentation on Probiotics Health 2025 Annual Results. The presentation will take around twenty, twenty five minutes followed by questions. So please feel free to submit questions during the presentation, and we'll do our best to answer as many of them at the end as possible. And if we do not manage to go through all of them, we will, put up the answers on the IMG portal afterwards.
1:01 So today's presenters, although you only see, the picture of me, today's presenters will be myself, CEO of the company, Steen Anderson. And my background spans more than, thirty years in the probiotic, and health ingredients sector with focus on scaling international businesses. I'm supported by our CFO, Mark Collingbourne, who brings, more than twenty years of financial and public company experience, with him. Mark, unfortunately, does not have his picture on here, but he is present and will also be able to answer questions at the end of the presentation. Okay. So sorry. I just so we will we will just before we get started, please take a second to familiarize yourself with our forward looking statement before we move on.
2:01 So 2025 has been a year of solid progress. We have delivered strong revenue growth. We have maintained robust margins, and we have continued to expand our commercial footprint across key markets. Importantly, this progress has been achieved while we still continue to invest in the business, both in the commercial capabilities, in manufacturing control and in clinical development to support the future, scalable and sustainable growth. During the year, we strengthened our customer base. We advanced our position in high potential markets such as Europe and China, and we further developed our pipeline of commercial opportunities.
2:49 At the same time, we have maintained financial discipline with a stable gross margin profile and a solid cash position that supports our path towards profitability. So 2005 marked a year of strong execution, growth and platform building for future scale. The presentation today will cover a number of topics. It will go through the, 2025 highlights. It will give you an insight into the financial review of the 2025 numbers. And we will also provide you with a little bit of insight on priorities and outlook for 2026 followed by Q and A.
3:38 But before we do that, I would like to start out spending a few minutes on presenting our technology platform and strategy to shareholders and potential new investors who might not be that familiar with the business. So really, our purpose as a company is to focus on developing and commercializing clinically validated probiotic based product solutions. And we have a particular focus on prevention within the cardiometabolic health segment. We operate to a scalable business to business model working with nutrition and health care companies across multiple markets.
4:27 Our value proposition is basically supported by our proprietary technology and, probiotic strain platform. The, the technology is taking offset in our LPLDL probiotic strain, which in several clinical trials, five clinical trials consistently have shown the ability to lower cholesterol levels by up to 37% and at the same time deliver a potential blood pressure reduction of up to 5%. We have protected the platform by 27 patents. And, that remains a key differentiator for probiotics. Importantly, is that this platform is not only scientifically validated, but it's also commercially very relevant.
5:20 It supports customer adoption, enables product differentiation, and it underpins our ability to build strong long term partnerships. The cardiometabolic market and the cardiometabolic health area remains one of the global leading health channel challenges. With more than twenty million deaths annually from cardiometabolic health issues, and a significant proportion of these are linked directly to elevated cholesterol levels where around four million people die globally every year. Importantly is that a large share of these cases is considered preventable.
6:12 Meaning with the right sort of changes to lifestyle, with the right prevention means, many of these cases and deaths can be avoided. And that continues to drive a demand for effective and accessible preventive consumer product solutions in the non OTC or in the non prescription area. At the same time, there are relatively few scientifically validated dietary supplement options available in this space, which puts us in a very unique position. This creates a clear and sustained opportunity for clinically supported active ingredients such as our LPLDL, strain.
7:03 And it also provides for clear opportunity in using that strain in finished product solutions where the key hero ingredient is our proprietary LPLDL strain. Our product offering is structured, to support both scalability and flexibility in how we engage with customers. We operate with two primary models. First, we have the model of selling bulk ingredients. Here, consumer customers are, having the opportunity to take our strain as a bulk strain and integrate our strain into their own formulations. This typically provides a shorter sales cycle of around nine to twelve months and allow us allows us to scale efficiently across multiple partners at the same time.
8:00 The second, part of our value proposition is to offer white label finished product solutions where we provide a more complex turnkey product, under our customers' consumer brand. This involves a longer sales cycle, typically eighteen to twenty four months, but at the same time allows for a deeper partnership and a higher value per customer. This dual approach enables us to, to balance near term revenue generation with longer term value creation as well as adapt to individual regional market needs. Our business model is designed to, be both scalable and capital efficient.
8:50 We focus on three pillars. We focus on clinical research and validation. We focus on consumer product development and we focus on business to business commercialization while leveraging external partners for manufacturing. This allows us flexibility and avoid heavy capital investment in production infrastructure while still maintaining control over quality and intellectual property linked to the strain on our technology platform. The model enables us to scale the business without a correspondent, corresponding increase in fixed cost, which supports margin stability and improves operating leverage over time. The model is a key factor, in our path towards profitability.
9:38 If we look at the at our geographical expansion, we, we follow a very disciplined and phased approach. We are currently active in Europe and North America, which represents established growth markets for us. In parallel, we are scaling in Asia Pacific, particularly China and Korea as well as looking into Australia and New Zealand, where we see a strong growth potential as well. Latin And South America represents a longer term opportunity, and we plan to enter these markets in a structured way as part of our phased rollout strategy. This phased approach, allows us to prioritize resources, manage risk and build sustainable position in each region before moving on into further new regions.
10:32 If we move on to the highlights of 2025, then 2025 was a year of strong commercial growth. Lead generation has increased to both our digital activities and our trade engagement, and we have expanded our active sales pipeline across all regions in 2025. This reflects the growth in our customer portfolio, which increased by 70% during 2025, 10 new product launches and entry into three new countries in 2025. All we're seeing, improved market engagement and a broader base of commercial opportunities entering the pipeline during the year.
11:22 We expect this to continue into 2026 with an estimated further customer expansion of approximately 45% this year as the pipeline converts into commercial agreements. This gives us increased visibility on future revenue and profitability development. In 2005, we significantly strengthened our commercial engine. Qualified leads increased by 47% to 280. That demonstrated targeted, improved targeted, targeting and execution. Website traffic doubled to 12,000 users, reflecting really a strong, brand visibility and digital engagement.
12:14 Importantly, digital campaigns now contribute to 20% of all, the leads, we are generating. We also increased industry presence through key trade shows, building credibility and partnership. Our pipeline now includes 76 active projects with 25 in advanced discussions. This is critical for near term revenue conversion and is proof of successful translation into stronger and more conversion ready pipeline long term. In 2025, we expanded into a new segment focused on menopause and cardiometabolic health.
13:04 This represents a large and underserved market of around, $26,000,000,000 at consumer level with an established clear correlation between menopause and cardiometabolic health. Seventy seven percent of all women above 45 years of age have elevated cholesterol. During, 2025 we opened 27 new sales projects in this segment. We expect the first of these to reach commercialization in mid late twenty twenty six. Our estimate is that the total medium term market potential for probiotics would be in the range of $25,000,000.
13:50 This is a clear example of how we are leveraging our platform into new applications and continue to grow the business by expanding it into new areas of use. China was another area, or another key driver for us. It's becoming a key growth driver for PROBIOTIX in general. The partnership established with Kemen, last year to position LPLDL, under Kemen's Vasonex brand is developing rapidly. Kemen has made significant investments in brand building, in visibility, including WeChat campaigns, webinars, trade media presence and participation in major trade shows.
14:38 Or maybe most important, commercial traction is already exceeding expectations. 2025 sales surpassed the contractually agreed volumes by 100%. And momentum continues into 2026 with projections indicating further outperformance this year. We have more than 50 customers testing the product as we speak with two product launches already completed in 2025. China is transitioning from an investment phase into a high growth revenue generating market with significant upside potential. So I think that sort of concluded some of the highlights for 2025 and hopefully are showing positive progress we have been making during last year. So I think I would like to hand it over to you, Mark, to take us through the financial review, please.
15:39 Okey doke. Good morning, everybody. All right. As Steen says, we've had a very strong year, and we have our sales up to £2,700,000 from £1,800,000 So we're up 45%. And our EBITDA, has come down to four the losses come down to $426,000 As well as that, we still have a gross margin, which has gone up slightly. In 2024, it was 53%. In 2025, we've it's up marked up a little bit to 54%. So this backs up the strong year. We've had increased sales. The EBITDA loss is coming down, so everything is progressing well.
16:30 How is that strong growth been achieved? Well, as you can see across most of our across our three main markets, we have increases in every one. So in NAFTA, we are up to 1,800,000 from 1.45. Now, as everybody knows, our main client is within that region. But what is particularly pleasing is that previously, that main client has been has accounted for 74% sales. In 2025, that has come down to 66 of sales, and that client's client's the revenue from that client is continuing to increase. So we have more customers.
17:18 Customers All are still the revenue is increasing, so it drives the strong growth. In the EMEA region, we're up 31%. And this again is new customers. That's that's driving the increase in turnover. And in the rest of the world, that is mainly due to our strategic partnership with Kemen as Steen has outlined previously. Right. Graph shows you, basically where we started off from with the balance out. The cash balance as at 2024 was 1,600,000, and we've ended up at 2025, but one with 1,200,000.
18:09 So we have a strong cash balance at the end of the year. So, obviously, we moved through this, and we have 2,700,000,000 of sales, 1,250,000 of cost of goods. So that gets you to your 54% gross profit. Our admin costs are up 9%, which as outlined in the RNS is fairly modest increase with very little fixed assets. Our debtors have come down year on year at the end of the year by 94 k, which is very pleasing, shows we have strong control of our debt. All of our debtors pay on time. We've not had any issues with bad debts. And our creditors are up slightly at the year end, but that's more to do with the phasing of the invoices.
18:59 And the last point on this slide, as highlighted in the RMS this morning, is quarter one twenty twenty six is profitable. So we're everything points to strong growth, and we're moving ahead. And now I'll hand back to Steen. Thank you, Mark. And for the last part of the presentation, we would like to just give you a little bit of insight into, sort of our priorities for this year and a few of the areas where we are very excited about the opportunities and the development so far.
19:46 So if we look at the overall, focus for this year, it, then our strategy remains, as you could see from the bullet points, it remains highly focused and execution driven. We are obviously expanding our presence in The U. S. Where we have a particular focus on establishing a stronger platform in The US to mitigate any risk of tariffs being imposed by the Trump administration. So that goes for manufacturing, identifying contract manufacturers in The US, but that's really on the top of our agenda for this year to to mitigate any potential risk there.
20:39 At the same time, we are supporting growth in China, and we are opening new markets, in Australia and New Zealand to further push our business and our access into the remaining part of the APAC region, where Australia and New Zealand traditionally are strongholds for exporting products into that part of the region. At the same time, we are optimizing our contract manufacturing setup as this is one of the key means to increase profitability and increase gross margins further. We have already, this year, managed to have progress in that area, but there is much more potential as we grow the business and we have more volume to leverage with.
21:35 So we believe that there should be a strong focus on continuing to optimize our relationship with contract manufacturers to use that to increase profitability. Innovation remains key and central with new strains and clinical platforms under development. We have a new strain planned for commercialization in 2026. It's one of the strains we originally identified as part of maturing the LPLGL strain. But this strain will help us to create differentiation in the market and thereby add additional business opportunities. We also, are positioning ourselves this year to capitalize on a regulatory driven market shift, where Monoclin K, a known ingredient in the dietary supplement industry for lowering cholesterol levels in the future will be potentially be banned, from use in the European market.
22:42 So if we just go to the the monoclonal case situation, it's it's a major regulatory shift, which is approaching. It's not yet approved by the European Union, but there are strong voices indicating that it will take place and that monoclonal k will be banned in The EU by 2027. As this is a hero ingredient in subcholesterol brands, this ingredient needs to be replaced. This will impact more than 40 supplement brands in Europe and impact a revenue of €130,000,000 in the European market. There are currently very few, compliant, clinically validated alternatives.
23:32 This creates a unique opportunity for LPLDL to become a leading replacement in that category. We have already initiated five products projects, sorry, and we have already secured, our first leading brand partnership, which we hopefully will be able to announce later this year, but it's, for now, not on the market and therefore still confidential. We believe that the total opportunity represents, in the range of €26,000,000, which is addressable the addressable market for probiotics. And and and I think the take home message here is really that we are ideally positioned to tap into this, market, which has not been part of our strategy because it's an opportunity that has arisen outside our control, but we are really, positioned well to tap into this market opportunity.
24:32 The other thing I would like to highlight is our clinical expansion into new cardiometabolic health areas. We are, this year initiating, we already have ethical approval for this. We are expanding our clinical work beyond cholesterol and into the broader metabolic health area, and that includes diabetes. So we are initiating a clinical study including two ten patients across prediabetes, type one diabetes and type two diabetes. The study will assess both the traditional lipid and glycemic control parameters, but it will also allow us to tap into the emerging, area of gut brain access.
25:26 The a project like this, a clinical project like this, of course, well said that it it comes out with positive results, will really help opening the door for new health claims and product applications for LPLDL, as a strength in the market. The market opportunity is substantial with over five ninety million people with diabetes globally and six thirty five million with prediabetes. Recruitment of individuals, that's on track, and that will take place throughout 2026 and 2027. So really, are looking at a, we are very excited to have had the opportunity to engage in this project, and we believe that we are looking at a really potential and exciting new application area for our LPLGL strain depending on the outcome obviously of the study.
26:28 So before we turn to questions, the key takeaways and business highlights here is that, yes, we in 2025, we experienced 45% revenue growth with improved margins. We had a significant decrease in the EBITDA loss. We have expanded our customer base by 70%. And as Mark already alluded to, our dependency of single customers single customer has been reduced significantly. Even though this customer still grows, we have managed to build the customer base around this one customer much faster than this customer grows. We are in a solid financial position to reach future profitability, and we have really clear priorities for 2026.
27:23 We started the year, as Mark also mentioned, with a historically strong order book for Q1, 1,300,000. And I think Mark already alluded to the fact that we see EBITDA profitability in Q1, which gives us further promise for long term profitability for the company. So I think that concludes the official presentation. And that will leave us time for Q and A. There are some pre submitted questions, and I think we will just take them from the top. And maybe the first one is for you, Marc. I can read it out loud. Are you expecting to be cash flow positive this year? And do you have any revenue targets for the full year?
28:24 Mark, will you be kind enough to Well, give thank you. Yes. What we've announced this morning is we are, we have a profitability in the first quarter, but there's I we we have not put any forecast out in the market, and I think the profitability in the first quarter shows, you know, where we're at currently and where we're striving to get to. Yep. Very good. Thank you, Mark. Yep. Then there's another sorry, did you want to add more, Marc, to this? Or No, I didn't. No, I'm fine. Thank you.
29:09 Okay. So there's another question here. Are sales to seed expected to continue, growing? And the answer to that is yes, it continues to grow sales to seed, which we are very pleased to see. But the really strong and good thing about this year is that our other business is growing faster than the growth we see with seed, meaning that our dependency on seed health is getting lesser and lesser year by year. Okay. Then there is a question. A new drug, has passed a large Phase III clinical trial reducing LDL cholesterol by up to 60%. How can probiotics, compete with a new drug like this?
30:07 That's a really good question. Thank you for that question as well as the other questions. But, you could say probiotics health is not in the treatment, space. We are in the prevention space. So really, we are not trying to compete with drugs like statins or any new drugs coming on the market. Our whole strategy and philosophy is to help people taking care of their own lives and their own health before an issue like elevated cholesterol becomes a problem. So, basically, what we are offering so it fits really well into our strategy. What we are offering is for consumers to have a choice to pick a nonprescription drug that will help them maintain normal cholesterol levels or will help them reduce slightly elevated cholesterol levels and therefore help them stay out of the medical world and stay out of long term having to go on a prescription drug like the ones, the one mentioned here.
31:24 Yep. Then there is a, a couple of years ago, I could buy a pill just containing LPLDL. That is no longer available. So do you have plans to bring that option back as it is what I want to purchase? Again, a great question. Our strategy, our strategy going forward is to really strengthen the focus on LPLDL in itself, which means that many of the products being brought on the European market, the global market today, are products, based only on LPLDL and not, add on ingredients. The the main reason in some of these cases that we added in the past, added other ingredients to the to the to LPLDL is really to strengthen our ability to put health, structure function claims on the product.
32:28 So if, for instance, a B vitamin is added to a product, there are certain within the European Union, certain regulations allowing you to come a structure function claim on the product. On a pure, LPLDL or pure probiotic product, you are not allowed to put health claims on. So that's a way to mitigate the the challenge there. But that being said, our strategy is to focus on the pure LPLDL as an ingredient and as a finished product. And you will see more products being brought on the market only containing that, that ingredient going forward. Yeah. And then there is a, good morning.
33:16 Is it possible you could keep the market more informed and of progress being made throughout the year? Thank you. I absolutely, I think we have promised the market to keep the market updated. We are trying to do that on a more regular basis, and we will continue to focus on sending out RNAs whenever our customers, or partners allow us to do it. The challenge is that in some cases, our customers do not allow us to do that, and therefore, we are restricted on the information we can bring out to the market. And some of the launches or many of the launches from last year, the partners weren't really, allowing us to make that information public.
34:04 But we we will take the point and we will do our best and continue to do our best to keep the market informed. Yes. Then there is a question. The record Q1 order book suggests strong demand for how demand. How confident are you in converting this into full year outperformance? Mark, will you comment on that, please? Yes. Certainly. There's there's there's not a lot I can comment on that. What I can see is that, obviously, q one order book, 1,300,000 profitability. That's a good start. That's what we're aiming for. We're aiming to keep going and consolidate our first quarter.
34:55 Thank you, Mark. And then you mentioned strong demand for science backed solutions. Are you seeing increasing inbound interest from larger partners? We absolutely are. We see that, the investment we have made in branding probiotics, in branding LPL, DL in the market is, now really starting to pay off. We see a change in the market among the larger players, where focus is now becoming on differentiation in the probiotic segment away from gut health and general well-being towards more indication and science based solutions.
35:43 One of the I spoke about this Monoclin K and the potential ban of Monoclin K in Europe. As I said, we have entered into one to an agreement with a European partner, which is a a a leading brand in a in a certain European country. And I think that will will show when we can when we can make that public, that will show you that that we see an increasing interest from not just the small players, from the larger, global or regional players to enter into this space. Yeah. And then there's a question. Monoclin K is in co biome CEAs. So is that going to reduce the sales of that product?
36:38 That is a very, very valid and good question. The the monoclonal k, eventually, if it's banned, the monoclonal k will be taken out of that of that product and reformulation will have to take place. So the short answer is yes. Eventually, it will impact sales of that product. But hopefully, we will be manage we will be able to manage to substitute for one of the other product solutions we have available, when we get closer to, to, to the date of the potential ban. This is really the process we are we have ongoing already today, with all the the brands using, not all, but I should say many of the brands using Monoclin K in their products today, including our own COBIOTIX brand.
37:33 We are in dialogue to make a shift away from that. Yes. Then there's one last question for you, Mark. Can you please explain further the share based payments charge? Yes, of course, I can. Share based payments charge is a method by which, you try you recognize, a cost in the p and l for the options which are are, given to directors and staff. It is governed by, International Financial Reporting Standards number two, and there is a very defined way of calculating it and there is set of rules, etcetera.
38:21 The most important thing to know about share based payments charge is it's not a cash cost. It is a it is an accounting entries which are put in the p and l and then the reversed the reversed out through the reserves. It's, but as I say, the most important thing to note is it's not an accounting charge. This is why you will see within, accounts of not just PROBIOTIX but other PLCs where they list the EBITDA before the share based payments because the EBITDA that's the continuing operations, the share based payments charge is an accounting entry. I hope that covers it. Thank you, Mark. And that basically ends, it ends the list of questions.
39:12 And so I would just like to take the, before we end this call, I would just like to take the opportunity to thank you, all of you, all the investors in the in in Probiotic Health. Thank you for your trust in us. We will, continue to do our very, very best not to disappoint you. I think there is a, a bright future ahead. We have, in over the past few years, investments in getting the brand known, in getting the pipeline built and what we saw in 2025, and we will see to an even larger extent in 2026, at least it's my belief that we will see that is that we will start having or seeing return on that investment, and we will start seeing a further acceleration of the customer base.
40:12 So thank you very much for joining today, and thank you for your continued support of the company. That's great. Steen, Mark, thank you very much indeed for updating investors today. Could you please ask investors not to close the session as you'll now be automatically redirected to provide your feedback, which will help the company better understand your views and expectations. On behalf of the management team, we'd like to thank you for attending today's presentation, and good morning to you all.
Follow ProBiotix Health PLC into a list and get an email when it puts out news.
CEO at PROBIOTIX HEALTH PLC
CFO at PROBIOTIX HEALTH PLC